The goal of the institute for DiagNostic Accuracy (iDNA) is to reduce lung cancer mortality across the globe. By making screening and early detection of lung cancer a reality for many, we aim to reduce the incredible burden lung cancer has on the lives of patients and their families.

Learn more

Worldwide four people die of lung cancer every minute. If lung cancer is detected at an early stage, the five-year survival rate is 56%. However, only 16% of lung cancer cases are diagnosed at such an early stage: more than 50% of people are diagnosed with lung cancer in a late stage, when the disease has already metastasized to other organs. Once the cancer has metastasized, the five-year survival rate is only 5%. Lung cancer is often detected too late for effective treatment, and more than half of the diagnosed patients die within a year.

Learn more

The survival rates for lung cancer can only be increased when the cancer is detected at its earliest stages. The only scientifically proven method of achieving early stage detection is through screening with lose-dose CT scans. iDNA’s mission is to create a stage shift in the detection of lung cancer, as we aim to detect most newly diagnosed lung cancers in an early stage. In the NELSON study, 69% of all screen-detected detected cancers were found in stage I. iDNA uses the same protocol to ensure the efficient, cost-effective implementation of the highest quality cancer screening.

Learn more

Early detection of lung cancer is key. Once detected, the proper and timely treatment of the cancer are essential for reducing mortality. iDNA facilitates academic institutions, as well as companies that focus their R&D on innovative diagnostic tooling and treatments that help lung cancer patients. Our global clinical trial infrastructure and in-house expertise provide our partners with unique opportunities to research or validate new technologies and drugs that localise and target cancers. This will positively impact lung cancer patients and doctors by expanding the available treatment options.

Learn more